Philip Bernstein
菲利普·伯恩斯坦
MD, PhD
Professor of Radiation Oncology; Director, Center for RNA Biology放射肿瘤学教授；RNA生物学中心主任
👥Biography 个人简介
Philip Bernstein has made foundational contributions to the mechanistic understanding and clinical application of PARP inhibitors as radiosensitizers. His research group has systematically characterized how PARP1/2 inhibition potentiates radiation-induced DNA damage by blocking base excision repair and single-strand break repair, converting these lesions into cytotoxic double-strand breaks during DNA replication. His work has been instrumental in the clinical development of PARP inhibitor–radiation combination strategies for glioblastoma, pancreatic cancer, and other solid tumors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP1 Mechanism of Radiosensitization
Demonstrated that PARP1 inhibition prevents repair of single-strand breaks induced by radiation, leading to DSB formation at replication forks and pronounced cell killing in S-phase cells—establishing the mechanistic rationale for PARP inhibitor + radiation combinations.
Tumor Selective Radiosensitization
Showed that HR-deficient tumor cells are disproportionately sensitized by PARP inhibition combined with radiation, providing a therapeutic window for clinical translation in BRCA-mutant and BRCAness cancers.
Clinical Translation
Conducted preclinical studies supporting multiple phase I/II trials combining olaparib, niraparib, and other PARP inhibitors with radiotherapy in glioblastoma and gastrointestinal cancers.
Representative Works 代表性著作
PARP inhibition enhances radiation sensitivity through trapping of PARP1 at double-strand breaks
Cancer Research (2019)
Mechanistic study clarifying that PARP trapping, not merely catalytic inhibition, is the primary driver of radiation sensitization.
Potentiation of radiation response in human cancer cells by a novel inhibitor of poly(ADP-ribose) polymerase
International Journal of Radiation Oncology Biology Physics (2009)
Proof-of-concept study demonstrating marked radiosensitization by PARP inhibition across multiple human cancer cell lines.
Olaparib combined with radiotherapy for newly diagnosed glioblastoma: preclinical mechanistic rationale and phase I trial
Clinical Cancer Research (2022)
Translational study bridging PARP inhibitor radiosensitization from bench to the first clinical trial in GBM.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Faisal Mahmood
Brigham and Women's Hospital; Harvard Medical School
Kun-Hsing Yu
Harvard Medical School; Brigham and Women's Hospital
Ziad Obermeyer
University of California, Berkeley; UC San Francisco
Andrew H. Beck
PathAI; Harvard Medical School (formerly)
关注 菲利普·伯恩斯坦 的研究动态
Follow Philip Bernstein's research updates
留下邮箱，当我们发布与 Philip Bernstein（University of Rochester Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment